Aortic Valve Replacement Devices Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Sutureless Valve and Mechanical Valve), Surgery (Minimally Invasive Surgery and Open

Aortic Valve Replacement Devices Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Sutureless Valve and Mechanical Valve), Surgery (Minimally Invasive Surgery and Open Surgery), End User (Hospitals & Clinics, Ambulatory Surgery Centers, and Others), and Geography

The aortic valve replacement devices market is expected to grow from US$ 7,113.39 million in 2022 to US$ 18,070.32 million by 2030; it is estimated to grow at a CAGR of 12.4% from 2022 to 2030. The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the rising number of aortic valve replacement surgeries and increasing demand for minimally invasive techniques are driving the aortic valve replacement devices market size and growth. Additionally, Increasing Number of Clinical Studies is likely to emerge as a significant trend in the market during the forecast period. However, product recalls of aortic valve replacement devices hinders market growth during the forecast period 2022-2030.

The increasing demand for minimally invasive techniques in aortic valve replacement surgeries reflects a significant shift in medical practice and patient preferences. In a minimally invasive aortic valve replacement, a poorly working aortic valve is replaced with an artificial valve. This trend is driven by the desire to minimize the invasiveness of procedures, reduce the associated risks, and promote faster recovery times. Minimally invasive approaches typically involve smaller incisions and the use of specialized instruments and technologies to access the heart, which can lead to shorter hospital stays and less scarring. Moreover, patients often experience less pain and a quicker return to their daily activities. Surgeons have embraced these techniques due to their potential benefits, and advancements in medical devices and surgical skills have further facilitated widespread adoption. As a result, healthcare institutions are investing in training their medical teams and acquiring the necessary equipment to meet the increasing demand for minimally invasive aortic valve replacement surgeries, thereby providing patients with improved treatment options and enhanced overall healthcare experiences.

Increasing Number of Clinical Studies Advancement is likely to emerge as a significant trend in the Aortic Valve Replacement Devices market.

A surge in research activity is driven by several factors, including growing prevalence of aortic valve diseases, advancements in medical technology, and need for more evidence-based approaches to treatment. Clinical studies are crucial in assessing the safety and efficacy of new surgical techniques, prosthetic valves, and transcatheter interventions. These studies also help identify risk factors, optimize patient selection criteria, and evaluate long-term outcomes to improve patient care and quality of life. As the demand for aortic valve replacement continues to rise, so does the importance of conducting robust clinical trials to provide healthcare professionals and patients with the best available evidence for making informed treatment options. With ongoing research and collaboration between medical institutions, the future of aortic valve replacement looks promising, with the potential for even more innovative and effective approaches on the horizon.

A few technological advancements by the players in the aortic valve replacement devices are mentioned below:

Trial started in January 2019, innovative device for pain management by millimeter band radiation: electronic-pain killer (EPIKARD).

Trial started in January 2017, vascular closure device in transcatheter aortic valve replacement. Evaluation of the safety and efficacy of a percutaneous plug-based large-bore vascular closure device for femoral artery closure in an unselected consecutive patient cohort undergoing transcatheter aortic valve implantation in a single-center prospective study.

The aortic valve replacement devices market is segmented based on product, surgery, and end user. Based on product, the aortic valve replacement devices market is bifurcated into mechanical valve and sutureless valve. The sutureless valve segment held the larger market share in 2022 and the same segment registered a significant CAGR in the aortic valve replacement devices market in 2022-2030.

Based on surgery, the aortic valve replacement devices market is bifurcated into open surgery and minimally invasive surgery. The minimally invasive surgery segment accounted for the larger market share in 2022 and the same segment is expected to register the higher CAGR during the forecast period.

By end user, the aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment accounted for the largest market share in 2022.

Various organic and inorganic strategies are adopted by companies in the aortic valve replacement devices market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios.A few of the significant developments by key players in the aortic valve replacement devices market are listed below.

In February 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).
In January 2023, Abbott received the U.S. Food and Drug Administration (FDA) approval for the company's latest generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases.